SpyGlass Pharma, Inc. (SGP)
24.00
-0.72
(-2.91%)
USD |
NASDAQ |
Oct 16, 16:00
24.16
+0.16
(+0.67%)
After-Hours: 20:00
SpyGlass Pharma Enterprise Value : 570.16M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 570.16M |
| October 15, 2026 | 594.24M |
| October 14, 2026 | 559.79M |
| October 13, 2026 | 567.48M |
| October 12, 2026 | 598.92M |
| October 09, 2026 | 600.93M |
| October 08, 2026 | 590.89M |
| October 07, 2026 | 566.81M |
| October 06, 2026 | 596.25M |
| October 05, 2026 | 623.34M |
| October 02, 2026 | 600.93M |
| October 01, 2026 | 653.77M |
| September 30, 2026 | 637.05M |
| September 29, 2026 | 618.32M |
| September 28, 2026 | 636.38M |
| September 25, 2026 | 672.84M |
| September 24, 2026 | 692.24M |
| September 23, 2026 | 709.29M |
| September 22, 2026 | 727.02M |
| September 21, 2026 | 702.60M |
| September 18, 2026 | 740.06M |
| September 17, 2026 | 748.43M |
| September 16, 2026 | 724.01M |
| September 15, 2026 | 736.05M |
| September 14, 2026 | 726.02M |
| Date | Value |
|---|---|
| September 11, 2026 | 687.89M |
| September 10, 2026 | 680.86M |
| September 09, 2026 | 687.22M |
| September 08, 2026 | 734.71M |
| September 04, 2026 | 735.38M |
| September 03, 2026 | 737.05M |
| September 02, 2026 | 713.31M |
| September 01, 2026 | 665.81M |
| August 31, 2026 | 640.39M |
| August 28, 2026 | 651.10M |
| August 27, 2026 | 668.15M |
| August 26, 2026 | 658.46M |
| August 25, 2026 | 657.12M |
| August 24, 2026 | 645.75M |
| August 21, 2026 | 654.11M |
| August 20, 2026 | 644.74M |
| August 19, 2026 | 678.19M |
| August 18, 2026 | 631.70M |
| August 17, 2026 | 629.69M |
| August 14, 2026 | 643.74M |
| August 13, 2026 | 609.29M |
| August 12, 2026 | 612.63M |
| August 11, 2026 | 598.59M |
| August 10, 2026 | 608.95M |
| August 07, 2026 | 613.97M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.895B |
| Corcept Therapeutics, Inc. | 11.59B |
| Veru, Inc. | 16.11M |
| Johnson & Johnson | 643.72B |
| Eli Lilly & Co. | 1.229T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.86M |
| Total Expenses (Quarterly) | 19.86M |
| EPS Diluted (Quarterly) | -0.5939 |
| Earnings Yield | -8.01% |
| Normalized Earnings Yield | -8.01 |